Giampietro Gasparini

13.7k total citations · 3 hit papers
170 papers, 9.8k citations indexed

About

Giampietro Gasparini is a scholar working on Oncology, Molecular Biology and Cancer Research. According to data from OpenAlex, Giampietro Gasparini has authored 170 papers receiving a total of 9.8k indexed citations (citations by other indexed papers that have themselves been cited), including 100 papers in Oncology, 62 papers in Molecular Biology and 61 papers in Cancer Research. Recurrent topics in Giampietro Gasparini's work include Angiogenesis and VEGF in Cancer (47 papers), Cancer Treatment and Pharmacology (42 papers) and Breast Cancer Treatment Studies (31 papers). Giampietro Gasparini is often cited by papers focused on Angiogenesis and VEGF in Cancer (47 papers), Cancer Treatment and Pharmacology (42 papers) and Breast Cancer Treatment Studies (31 papers). Giampietro Gasparini collaborates with scholars based in Italy, United States and United Kingdom. Giampietro Gasparini's co-authors include Adrian L. Harris, F. Pozza, Noel Weidner, Pierantonio Bevilacqua, Raffaele Longo, S Meli, Elizabeth N. Allred, Dan H. Moore, J Folkman and Patrizia Boracchi and has published in prestigious journals such as Journal of Clinical Oncology, Blood and JNCI Journal of the National Cancer Institute.

In The Last Decade

Giampietro Gasparini

168 papers receiving 9.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Tumor Angiogenesis: A New Significant and Independent Prognostic Indicator in Early-Stage Breast Carcinoma

1992 1.5k citations Noel Weidner, F. Pozza et al. JNCI Journal of the National Cancer Institute profile →
Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation

1996 631 citations Giampietro Gasparini, Noel Weidner et al. European Journal of Cancer profile →
Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study

2009 446 citations Giampietro Gasparini et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Giampietro Gasparini Italy	43	5.0k	4.1k	3.4k	1.5k	978	170	9.8k
J. Torhorst Switzerland	36	4.1k 0.8×	3.7k 0.9×	2.2k 0.7×	1.7k 1.2×	861 0.9×	119	8.9k
H. Graeff Germany	44	2.0k 0.4×	2.2k 0.5×	4.0k 1.2×	1.0k 0.7×	1.3k 1.3×	210	7.5k
Emily K. Bergsland United States	45	3.1k 0.6×	7.1k 1.7×	1.6k 0.5×	1.8k 1.2×	677 0.7×	202	10.9k
Peter Birner Austria	49	3.3k 0.7×	4.0k 1.0×	2.2k 0.6×	2.1k 1.5×	487 0.5×	169	9.0k
Nils Brünner Denmark	56	4.0k 0.8×	4.1k 1.0×	5.0k 1.5×	917 0.6×	371 0.4×	238	9.9k
Stefan Holdenrieder Germany	48	3.9k 0.8×	2.4k 0.6×	3.3k 1.0×	1.6k 1.1×	391 0.4×	265	8.7k
Gabriella Fontanini Italy	56	5.3k 1.1×	7.2k 1.8×	2.7k 0.8×	4.7k 3.2×	850 0.9×	320	13.4k
Massimo Aglietta Italy	58	3.6k 0.7×	7.1k 1.7×	1.9k 0.6×	2.8k 2.0×	1.5k 1.5×	397	14.5k
Dick J. Richel Netherlands	43	3.5k 0.7×	4.5k 1.1×	2.2k 0.6×	1.7k 1.1×	270 0.3×	107	9.6k
Ronit Simantov United States	36	5.5k 1.1×	3.3k 0.8×	2.6k 0.8×	4.3k 2.9×	647 0.7×	88	11.2k

Countries citing papers authored by Giampietro Gasparini

Since Specialization

Citations

This map shows the geographic impact of Giampietro Gasparini's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Giampietro Gasparini with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Giampietro Gasparini more than expected).

Fields of papers citing papers by Giampietro Gasparini

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Giampietro Gasparini. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Giampietro Gasparini. The network helps show where Giampietro Gasparini may publish in the future.

Co-authorship network of co-authors of Giampietro Gasparini

This figure shows the co-authorship network connecting the top 25 collaborators of Giampietro Gasparini. A scholar is included among the top collaborators of Giampietro Gasparini based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Giampietro Gasparini. Giampietro Gasparini is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Scavo, Maria Principia, Annalisa Cutrignelli, Nicoletta Depalo, et al.. (2020). Effectiveness of a Controlled 5-FU Delivery Based on FZD10 Antibody-Conjugated Liposomes in Colorectal Cancer In vitro Models. Pharmaceutics. 12(7). 650–650. 19 indexed citations

Schirosi, Laura, Simona De Summa, Stefania Tommasi, et al.. (2017). VEGF and TWIST1 in a 16‐biomarker immunoprofile useful for prognosis of breast cancer patients. International Journal of Cancer. 141(9). 1901–1911. 10 indexed citations

Longo, Raffaele, et al.. (2013). Atypical Multiple Ileum Metastases of Renal Cell Carcinoma. Journal of Gastrointestinal Cancer. 44(4). 477–480. 1 indexed citations

Amadori, D., Carlo Milandri, G. Comella, et al.. (2011). A phase I/II trial of non-pegylated liposomal doxorubicin, docetaxel and trastuzumab as first-line treatment in HER-2-positive locally advanced or metastatic breast cancer. European Journal of Cancer. 47(14). 2091–2098. 20 indexed citations

Torino, Francesco, Salvatore Maria Corsello, Raffaele Longo, Agnese Barnabei, & Giampietro Gasparini. (2009). Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy. Nature Reviews Clinical Oncology. 6(4). 219–228. 158 indexed citations

Tortora, Giampaolo, Fortunato Ciardiello, & Giampietro Gasparini. (2008). Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applications. Nature Clinical Practice Oncology. 5(9). 521–530. 94 indexed citations

Longo, Raffaele, et al.. (2007). Integrated therapy of kidney cancer. Annals of Oncology. 18. vi141–vi148. 25 indexed citations

Ranieri, Girolamo, Rosa Patruno, Alfredo Zito, et al.. (2007). A possible role of thymidine phosphorylase expression and5‐fluorouracil increased sensitivity in oropharyngeal cancer patients. Journal of Cellular and Molecular Medicine. 11(2). 362–368. 25 indexed citations

Gasparini, Giampietro, Massimo Gion, Luigi Mariani, et al.. (2006). Randomized Phase II Trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer. Breast Cancer Research and Treatment. 101(3). 355–365. 107 indexed citations

10.

Mocini, David, Raffaele Longo, Furio Colivicchi, et al.. (2005). A complete atrioventricular block secondary to myocardial metastases of lung cancer. A case report.. PubMed. 6(11). 931–2. 9 indexed citations

11.

Gasparini, Giampietro, et al.. (2005). Gefitinib (ZD1839) combined with weekly epirubicin in patients with metastatic breast cancer: a phase I study with biological correlate. Annals of Oncology. 16(12). 1867–1873. 19 indexed citations

12.

Stani, Simonetta Chiara, et al.. (2002). Antiangiogenic agents.. PubMed. 1(4). S39–43. 1 indexed citations

13.

Minischetti, Monica, Angelo Vacca, Doménico Ribatti, et al.. (2000). TNP‐470 and recombinant human interferon‐α2a inhibit angiogenesis synergistically. British Journal of Haematology. 109(4). 829–837. 38 indexed citations

14.

Gasparini, Giampietro & Marco Presta. (1996). Clinical studies with angiogenesis inhibitors: Biological rationale and challenges for their evaluation. Annals of Oncology. 7(5). 441–444. 25 indexed citations

15.

Bevilacqua, Pierantonio, Mattia Barbareschi, Paolo Verderio, et al.. (1995). Prognostic value of intratumoral microvessel density, a measure of tumor angiogenesis, in node-negative breast carcinoma ? results of a multiparametric study. Breast Cancer Research and Treatment. 36(2). 205–217. 83 indexed citations

16.

Gasparini, Giampietro. (1995). Biological and clinical role of angiogenesis in breast cancer. Breast Cancer Research and Treatment. 36(2). 103–107. 24 indexed citations

17.

Gasparini, Giampietro, F. Pozza, Pierantonio Bevilacqua, et al.. (1994). c-erbB-3 and c-erbB-2 protein expression in node-negative breast carcinoma—an immunocytochemical study. European Journal of Cancer. 30(1). 16–22. 65 indexed citations

18.

Gasparini, Giampietro, F. Pozza, & Adrian L. Harris. (1993). Evaluating the Potential Usefulness of New Prognostic and Predictive Indicators on Node-Negative Breast Cancer Patients. JNCI Journal of the National Cancer Institute. 85(15). 1206–1219. 193 indexed citations

19.

Gasparini, Giampietro, W.J. Gullick, Pierantonio Bevilacqua, et al.. (1992). Human breast cancer: prognostic significance of the c-erbB-2 oncoprotein compared with epidermal growth factor receptor, DNA ploidy, and conventional pathologic features.. Journal of Clinical Oncology. 10(5). 686–695. 87 indexed citations

20.

Gasparini, Giampietro. (1964). PROBLEMS OF ONCHOCERCIASIS IN NEW SUSPECTED AREAS: SOWDA AND ONCHOCERCIASIS.. PubMed. 45. 243–60. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact